Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19491909 | 0.95 | SPHK1 (0.37) | SPHK1 | |
| SCHEMBL18583670 | 0.95 | SPHK1 (0.37) | SPHK1 | |
| SCHEMBL20205239 | 0.95 | SPHK1 (0.37) | SPHK1 | |
| SCHEMBL21940826 | 0.94 | SPHK1 (0.36) | SPHK1 | |
| SCHEMBL20466350 | 0.90 | SPHK1 (0.33) | SPHK1 | |
| SCHEMBL22085914 | 0.89 | SPHK1 (0.31) | SPHK1 | |
| SCHEMBL24368039 | 0.89 | SPHK1 (0.35) | SPHK1 | |
| SCHEMBL20466313 | 0.85 | L3MBTL3 (0.31) | — | |
| SCHEMBL21214491 | 0.81 | — | — | |
| SCHEMBL26630932 | 0.79 | GNAO1 (0.49) | SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-10647694-B2 | Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof | ARROMAX PHARMATECH CO., LTD. (CN) | 2020-05-12 | — | — | US | disclosed |
| US-20190256493-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256493-A1 | DIPHENYLAMINOPYRIMIDINE AND TRIAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | ALK, CD2, TYRO3 | SPHK1 2388/4885 |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | SPHK1 4099/4885 |
| US-10647694-B2 | Diphenylaminopyrimidine and triazine compound, and pharmaceutical composition and use thereof | ALK, CD2, TYRO3 | SPHK1 2388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.